

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

**July 26, 2017**

---

**Lombard Medical, Inc.**  
(Exact Name of Registrant as Specified in Its Charter)

**Commission File Number 001-36402**

---

N/A  
(Translation of Registrant's Name into English)

**Cayman Islands**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**3841**  
(Primary Standard Industrial  
Classification Code Number)

**Not applicable**  
(I.R.S. Employer Identification  
Number)

**4 Trident Park  
Didcot  
Oxfordshire OX11 7HJ  
United Kingdom  
+44 20 1235 750800**  
(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

---

**Lombard Medical, Inc.**  
**4 Trident Park**  
**Didcot**  
**Oxfordshire OX11 7HJ**  
**United Kingdom**  
(Name, Address of Agent for Service)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_

---

Lombard Medical, Inc. (the “Company”) is announcing today that it plans to hold its 2017 Annual General Meeting of Shareholders (the “Annual Meeting”) on August 10, 2017 at 12:00 noon., British Summer Time, at the Company’s U.K. office located at Lombard Medical House, 4 Trident Park, Didcot, Oxfordshire, England, OX11 7HJ.

Pursuant to the Company’s Amended and Restated Memorandum and Articles of Association, the Company mailed a Notice of Annual Meeting and accompanying proxy statement to the Company’s shareholders of record as of June 16, 2017, copies of which are attached hereto and incorporated by reference herein.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Lombard Medical, Inc.**

Date: July 26, 2017

By: Kurt Lemvigh  
Kurt Lemvigh  
Chief Executive Officer

**INDEX TO EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Notice of Annual Meeting and Proxy Statement



June 26, 2017

Dear Shareholder:

On behalf of the Board of Directors, I am pleased to invite you to the 2017 annual general meeting of shareholders of Lombard Medical, Inc.

This letter serves as your official notice that the meeting will be held on August 10, 2017 at 12:00 noon, British Summer Time, at our U.K. office located at Lombard Medical House, 4 Trident Park, Didcot, Oxfordshire, England, OX11 7HJ.

This year you will be asked to vote on the following proposals:

1. To elect one Class III director to the Board of Directors to serve for a three-year term expiring at the 2020 annual general meeting of shareholders;
2. To consider and adopt the Company's annual audited financial statements for the fiscal year ended December 31, 2016; and
3. To ratify the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017.

The Board of Directors recommends a vote FOR proposals 1, 2 and 3. These proposals are described in the attached Proxy Statement, which you are encouraged to read fully. We will also consider any additional business that may be properly brought before the annual meeting.

The Board of Directors has fixed June 16, 2017 as the record date for the determination of shareholders entitled to notice of, and to vote at, the annual meeting and any adjournment or postponement thereof. Only holders of record of ordinary shares of the Company at the close of business on the record date are entitled to notice of, and to vote at, the annual meeting. At the close of business on the record date, the Company had 27,950,785 ordinary shares outstanding and entitled to vote.

It is important that your shares be represented at the annual meeting, so whether or not you plan to attend in person, please vote by proxy on the Internet at [www.proxyvote.com](http://www.proxyvote.com) or by completing, signing, dating and returning the enclosed proxy card in the envelope provided. Alternatively you can vote the proxy by phone at (888) 693-8683. If you attend the meeting, you may revoke your proxy and vote in person.

If your shares are held in the name of a bank, broker or other nominee, please follow the instructions on the voting instruction form furnished by that entity in order to vote your shares. Please note that if your shares are held in the name of a bank, broker or other nominee and you wish to vote at the meeting, you must first obtain a proxy issued in your name from that record holder prior to the meeting and bring the proxy to the meeting.

Sincerely,

Raymond W. Cohen  
Chairman, Director

---

**LOMBARD MEDICAL, INC.**  
**Lombard Medical House, 4 Trident Park, Didcot, England, OX11 7HJ**

**Proxy Statement for Annual General Meeting of Shareholders  
to be Held on August 10, 2017**

We are furnishing this Proxy Statement to shareholders (“**Shareholders**”) of record of Lombard Medical, Inc. (the “**Company**,” “**Lombard**,” “**Lombard Medical**,” “**we**” or “**us**”) in connection with the solicitation of proxies for use at the 2017 annual general meeting of shareholders to be held at at 12:00 noon, British Summer Time at our U.K. office located at Lombard Medical House, 4 Trident Park, Didcot, England, OX11 7HJ, and at any adjournments or postponements thereof (the “**Annual General Meeting**”).

At the Annual General Meeting, the Shareholders will be asked to:

1. Elect one Class III director to the Board of Directors of the Company (the “**Board**”) to serve for a three-year term expiring at the 2020 annual general meeting of shareholders;
2. Consider and adopt the Company’s annual audited financial statements for the fiscal year ended December 31, 2016; and
3. Ratify the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017.

**RECOMMENDATIONS OF OUR BOARD OF DIRECTORS**

Our Board recommends that you vote your shares as follows:

- **FOR** the election of our one Class III director nominee to the Board of Directors to serve for a three-year term expiring at the 2020 annual general meeting of shareholders;
- **FOR** the adoption of the Company’s annual audited financial statements for the fiscal year ended December 31, 2016; and
- **FOR** the ratification of the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017.

**PERSONS MAKING THE SOLICITATION**

We, on behalf of the Board, are soliciting proxies in connection with the Annual General Meeting. The Company will bear the costs of the solicitation.

**VOTING INFORMATION**

Shareholders of record of the Company’s ordinary shares, par value \$.01 per share (“**Ordinary Shares**”), at the close of business on June 16, 2017 (the “**Record Date**”), are entitled to notice of, and to vote at, the Annual General Meeting and any adjournment or postponement thereof. On the Record Date, 27,950,785 Ordinary Shares were outstanding and entitled to vote. Each outstanding Ordinary Share entitles the holder thereof to one vote on each matter submitted to the Shareholders for a vote. Pursuant to the Company’s Amended and Restated Memorandum and Articles of Association (the “**Articles**”) Shareholders representing not less than one-third the nominal value of the total issued Ordinary Shares must be represented at the meeting, either in person or by proxy, to constitute a quorum. There must be a quorum for the Annual General Meeting to be held.

Some of our Shareholders hold their shares through a stockbroker, bank or other nominee rather than directly in their own name. If you hold your shares in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares held in street name, and these materials are being forwarded to you by your broker or nominee, which is considered the Shareholder of record with respect to those shares. As the beneficial owner, you have the right to direct your broker or nominee how to vote and are also invited to attend the Annual General Meeting. However, since you are not the Shareholder of record, you may not vote those shares in person at the meeting unless you obtain a signed proxy from the Shareholder of record giving you the right to vote the shares. Your broker or nominee has enclosed or provided a voting instruction card for you to use to direct your broker or nominee how to vote these shares.

If a share is represented for any purpose at the Annual General Meeting by the presence of the registered owner or a person holding a valid proxy for the registered owner, it is deemed to be present for the purpose of establishing a quorum. Therefore, valid proxies which are marked “Abstain” or as to which no vote is marked, including broker non-votes (described below), will be included in determining the number of votes present or represented at the Annual General Meeting.

---

If you have questions of any nature, please call our Investor Relations department at +44 (0) 1235 750 849.

## Vote Required

Assuming that a quorum is present:

- With respect to Proposal No. 1, the director nominee will be elected if the number of Ordinary Shares voted for that director nominee exceed the number of Ordinary Shares voted against that director nominee.
- With respect to Proposal Nos. 2 and 3, each proposal will be approved if the number of Ordinary Shares voted in favor of the respective matter exceed the number of Ordinary Shares voted against that matter.

If a Shareholder submits a proxy but does not specify how he or she would like it to be voted, then the proxy will be voted “**FOR**” the election of the director nominee to the Board of Directors to serve for a three-year term expiring at the 2020 annual general meeting of shareholders, “**FOR**” the adoption of the Company’s annual audited financial statements for the fiscal year ended December 31, 2016, and “**FOR**” the ratification of the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017. We will not count abstentions, broker non-votes or the failure to return a signed proxy as either for or against these proposals, so abstentions, broker non-votes and, assuming a quorum is present, the failure to return a signed proxy, have no impact on Proposal Nos. 1, 2 and 3.

Brokers who hold shares for the accounts of their clients may vote these shares either as directed by their clients or in their own discretion if permitted by the exchange or other organization of which they are members. Proposals that brokers do not vote on are referred to as “broker non-votes.” A broker non-vote does not count as a vote in favor of or against a particular proposal for which the broker has no discretionary voting authority.

## Voting Procedures

Pursuant to the Articles, proxies must be received by the Company at least 48 hours prior to the time of the Annual General Meeting in order to be effective. Ensure that your shares can be voted at the Annual General Meeting by submitting your proxy card, or contacting your broker, bank or other nominee.

*If your shares are registered in your name*, please submit your proxy as soon as possible:

*Via the Internet.* You may vote via the Internet by going to [www.proxyvote.com](http://www.proxyvote.com) by following the instructions. You will need to have the shareholder number written on your proxy card available when voting via the Internet. If you want to vote via the Internet, you must do so before 11:59 p.m. EDT, on August 8, 2017. **If you vote via the Internet, you do not need to return a proxy card.**

*By Mail.* If you are a beneficial owner, you may vote by mail by signing and dating your proxy card or voting instruction card provided by your broker, bank or other nominee and mailing it in the postage-prepaid envelope provided. If you provide specific voting instructions, your shares will be voted as you instruct.

*Via Phone.* If your shares are registered in your name, you may vote by calling (888) 693-8683.

*If your shares are held in the name of a broker, bank or other nominee*, please follow the instructions on the voting instruction form furnished by such broker, bank or other nominee in order to vote your shares. Please note that if your shares are held in the name of a broker, bank or other nominee and you wish to vote at the Annual General Meeting, you must obtain a proxy issued in your name from that record holder prior to the meeting and bring the proxy to the meeting.

## Revocability of Proxy

A proxy may be revoked by a Shareholder prior to voting at the Annual General Meeting by written notice to the Company at Lombard Medical, Inc., Lombard Medical House, 4 Trident Park, Didcot, England, OX11 7HJ, by submission of another proxy bearing a later date, or by voting in person at the Annual General Meeting. Such notice or later proxy will not affect a vote on any matter taken prior to the receipt thereof by the Company. The mere presence at the Annual General Meeting of a Shareholder who has appointed a proxy will not revoke the prior appointment.

If not revoked, the proxy will be voted at the Annual General Meeting in accordance with the instructions indicated on the proxy card by the Shareholder or, if no instructions are indicated, will be voted “**FOR**” the election of the director nominee to the Board of Directors to serve for a three-year term expiring at the 2020 annual general meeting of shareholders, “**FOR**” the adoption of the Company’s annual audited financial statements for the fiscal year ended December 31, 2016, and “**FOR**” the ratification and appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017, and, as to any other matter that may be properly brought before the Annual General Meeting, in accordance with the judgment of the proxy.

---

## ANNUAL REPORT AND FINANCIAL STATEMENTS

A copy of the Company's Annual Report on Form 20-F (the "**Annual Report**") filed with the United States Securities and Exchange Commission (the "**SEC**") on May 1, 2017 is available on the Company's website at *lombardmedical.com* under "*Investor Relations*" and on the SEC's website at *sec.gov*. We encourage you to read the Annual Report for information about the Company, including:

- Financial performance;
- Risk factors that could materially and adversely affect the Company's business, financial condition and results of operations;
- Directors, senior management and employees;
- Certain beneficial owners of our Ordinary Shares and related party transactions; and
- Compensation of directors and officers.

You may obtain copies of our public filings, including the Annual Report, from our website at *lombardmedical.com* under "*Investor Relations*", or from the SEC's website at *sec.gov*. None of the other information on our website or *sec.gov* is incorporated into this proxy statement. You also may request a copy of these materials, without incurring any charge, by calling our Investor Relations department at +44 (0) 1235 750 849. Please make your request no later than July 27, 2017 to facilitate timely delivery. If you do not request materials pursuant to the foregoing procedures, you will not otherwise receive an e-mail or electronic copy of the materials.

---

**PROPOSAL NO. 1:  
ELECTION OF DIRECTORS**

One-third of our directors are elected annually by the Shareholders to serve for a three-year term, unless he or she resigns or is removed earlier. Our Class II directors are coming up for reelection. The Board currently consists of six members, as determined in accordance with the Articles. Our current directors are:

Raymond Cohen  
John Rush  
Jonathan Chen  
Martin Sun  
Michael Carrel

Our Class III director is listed below:

Michael Carrel

The names of the nominee being presented for consideration by the Shareholders, who is an incumbent director, and certain other information about him is set forth below.

**Michael H. Carrel**

Michael H. Carrel joined the Board on February 11, 2015. Mr. Carrel brings more than two decades of leadership experience and presently serves as the President and Chief Executive Officer of ArtiCure, Inc., (NASDAQ: ATRC), a leading medical device company focused on surgical treatments for atrial fibrillation and left atrial appendage management. Since joining AtriCure in November 2012, Mr. Carrel has led the company through significant revenue growth. Prior to joining AtriCure, Mr. Carrel was the President and Chief Executive Officer of Vital Images, a publicly traded medical imaging software company (Nasdaq: VTAL) from 2008 until it was sold to Toshiba in 2011. Mr. Carrel attended Pennsylvania State University for his undergraduate degree and the Wharton School at the University of Pennsylvania for graduate school.

**Vote Required**

Assuming a quorum is present at the Annual General Meeting, the director nominee will be elected if the votes cast in favor of that director nominee exceed the votes cast against that director nominee.

**The Board recommends that you vote FOR the election of Messr. Carrel as a director of the Company.**

**PROPOSAL NO. 2:  
ADOPTION OF THE COMPANY'S ANNUAL AUDITED FINANCIAL STATEMENTS FOR THE  
FISCAL YEAR ENDED DECEMBER 31, 2016**

Proposal No. 2 is to consider and adopt the Company's annual audited financial statements for the fiscal year ended December 31, 2016. These financial statements are publicly available on our website at [www.lombardmedical.com](http://www.lombardmedical.com) under "Investor Relations" or on the SEC's website at [www.sec.gov](http://www.sec.gov). None of the information on our website or SEC's website is incorporated by reference in the proxy statement.

**Vote Required**

If a quorum is present at the Annual General Meeting, this proposal will be approved if the votes cast in favor of the proposal exceed the votes cast against the proposal.

**The Board recommends that you vote FOR the adoption of the Company's annual audited financial statements for the fiscal year ended December 31, 2016.**

---

**PROPOSAL NO. 3:  
RATIFICATION OF THE APPOINTMENT OF  
BAKER TILLY VIRCHOW KRAUSE, LLP  
AS THE COMPANY'S  
INDEPENDENT REGISTERED PUBLIC ACCOUNTANT  
FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017**

Proposal No. 3 is to ratify the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017.

**Vote Required**

If a quorum is present at the Annual General Meeting, this proposal will be approved if the votes cast in favor of the proposal exceed the votes cast against the proposal.

**The Board recommends that you vote FOR the ratification of the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accountant for the fiscal year ending December 31, 2017.**

**OTHER MATTERS**

Other than what is described above, the Board is unaware of any additional items of business to be brought before the Annual General Meeting.